KZR-261 in Subjects With Advanced Solid Malignancies
Colon/Rectal Cancer
Eye Cancer
Melanoma
Prostate Cancer
Solid Tumor
Unknown Primary
18 Years and older, Male and Female
KZR-261-101 (primary)
NCI-2022-01096
Summary
A first-in-human, open-label, multicenter, Phase 1 study of KZR-261 designed to assess
the safety and tolerability, preliminary anti-tumor activity, and pharmacokinetics (PK)
of KZR-261, as well as identify the recommended Phase 2 dose (RP2D). The study comprises
a Part 1 (Dose Escalation) and a Part 2 (Dose Expansion) in solid organ tumors
(melanoma/uveal melanoma, mesothelioma, colorectal cancer, prostate cancer, and
"All-Tumors").
Objectives
The first-in-human, open-label, multicenter, Phase 1 study of KZR-261, Study KZR-261-101,
will be conducted in two parts (dose escalation and dose expansion) to evaluate the
safety and tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary
anti-tumor activity of KZR-261 in subjects with locally advanced or metastatic solid
malignancies for whom no therapeutics are available that can confer a reasonable
likelihood of clinical benefit. The 5 tumor cohorts in the dose expansion part include
advanced malignant:
- melanoma/uveal melanoma
- mesothelioma
- colorectal cancer
- castrate-resistant prostate cancer
- "All-Tumors"
Part 1 (Dose Escalation) and Part 2 (Dose Expansion) comprise a 4-week Screening Period,
a Treatment Period lasting approximately 24 weeks, 4-6-week Safety Follow-up, and a
12-month Long-Term Follow-up Period (after last dose of study treatment), for a total
study duration of approximately 20 months.
Eligibility
- Histologic or cytologic evidence of malignant solid tumor with advanced disease (except primary central nervous system [CNS] neoplasms), defined as cancer that is either metastatic or locally advanced and unresectable (and for which additional radiation therapy or other locoregional therapies are not considered to result in reasonable clinical benefit).
- Disease that is resistant to or relapsed following available standard systemic therapy, or for which there is no standard systemic therapy or reasonable therapy in the Investigator's judgement likely to result in clinical benefit, or if such therapy has been refused by the subject. Documentation of the reason must be provided for subjects who have not received a standard therapy likely to result in clinical benefit.
- Eastern Cooperative Oncology Group Performance Status score of 0 or 1.
- Adequate baseline hematologic and organ function.
- Willing to use contraception. Additional Inclusion for Part 2: Histologic or cytologic evidence of malignancy
(melanoma/uveal melanoma, colorectal cancer, prostate cancer, mesothelioma).
Treatment Sites in Georgia
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials.